DPP‐4/SGLT2 inhibitor combined therapy for type 2 diabetes
Sign Up to like & getrecommendations! Published in 2017 at "Prescriber"
DOI: 10.1002/psb.1626
Abstract: DPP‐4 inhibitors and SGLT2 inhibitors lower blood glucose by complementary mechanisms of action, and two fixed‐dose combinations – Qtern and Glyxambi – have now been approved for the treatment of type 2 diabetes. This article… read more here.
Keywords: inhibitor combined; dpp sglt2; sglt2 inhibitor; combined therapy ... See more keywords
PD-1 inhibitor combined with radiotherapy and GM-CSF as salvage therapy in patients with chemotherapy-refractory metastatic solid tumors.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.15_suppl.e15173
Abstract: e15173Background: Patients with refractory metastatic solid tumors have poor prognoses and few therapeutic options. The application of PD-1 inhibitor has led to a paradigm shift in the treatment of... read more here.
Keywords: inhibitor combined; solid tumors; radiotherapy csf; refractory metastatic ... See more keywords
PD-1 inhibitor combined with apatinib for advanced gastric or esophagogastric junction cancer: a retrospective study
Sign Up to like & getrecommendations! Published in 2020 at "Translational cancer research"
DOI: 10.21037/tcr-20-1333
Abstract: Gastric or esophagogastric junction cancer (GC/EGJC) is the third leading cause of cancer-related deaths worldwide, with most of the cases diagnosed at late stages (1,2). For patients (pts) with unresectable or recurrent advanced GC/EGJC, systemic… read more here.
Keywords: gastric esophagogastric; inhibitor combined; junction cancer; cancer ... See more keywords